NEW YORK, NY, July 12, 2013 - (eTeligis via ACCESSWIRE) IntelliCell BioSciences, Inc. (OTC PINK: SVFC), a developer of novel, patented stromal vascular fraction cells (stem cells) technologies that address the regenerative, curative and preventative conditions of disease states, announces an online interview where they discuss their current SVF (stem cell) treatment technology.
Dr. Steven Victor, the Chairman and CEO of IntelliCell BioSciences, Inc. conducted an online interview where he discusses the company's current SVF (stem cell) treatment technology, and prospects for their patented extraction technology in healthcare facilities in the US.
To access the online interview please visit http://www.wallstreetnewscast.com/profile/svfc.html
Register for Mailing List
If you would like to be added to SVFC mailing list, receive updates, or submit a question to the company, please register online at http://www.wallstreetnewscast.com/request/svfc.html
About IntelliCell BioSciences
IntelliCell BioSciences is a Regenerative Medicine company developing novel technologies that address the regenerative, curative and preventative conditions of disease states with high unmet clinical needs. The Company has patented technology for the use of ultrasonic cavitation for separating stromal vascular fraction with stem cells from adipose tissue and several patent-pending. The Company is also pioneering the development of autologous and allogeneic cells from living and non-living tissue donors for research purposes. IntelliCell is planning a series of in-human clinical studies with top tier universities for the treatment of cardiac disease, osteoarthritis, multiple sclerosis, lower limb ischemic wounds, and gum regeneration in the oral cavity as well as medical aesthetics. The Company has developed a first class cGTP cellular processing facility in New York City, purpose built and designed to be fully integrated into an ambulatory surgery center and hospitals. http://www.intellicellbiosciences.com
Forward-Looking Statements
This news release contains forward-looking statements regarding IntelliCell BioSciences, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties that may cause actual results and future achievements of IntelliCell BioSciences to be materially different from those implied by these forward-looking statements. IntelliCell BioSciences has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
Contact:
Excerpt from:
IntelliCell BioSciences Discusses their Stem Cell Treatment Technology in Online Interview